Free Shipping for orders over $49 within the U.S.
WALNUT, CALIF. (PRWEB) FEBRUARY 05, 2020
Just in time for American Heart Health Month, Farlong Pharmaceutical, a vertically integrated, plant-based ingredient and supplement company, announces the clinical trial results from a randomized, placebo-controlled, double-blind, parallel study on one hundred healthy adults to determine the effect of Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract) on cholesterol and blood pressure, conducted December 2016 through June 2019.
The findings of this study demonstrate that Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract) supplementation is well tolerated and has a positive influence on reducing the risk of cardiovascular disease by decreasing blood pressure and selectively increasing HDL-C.
Sponsored by Farlong Pharmaceutical and conducted by KGK Science, Inc., the primary objective was the difference in serum LDL-C from baseline to week 12 between Farlong NotoGinseng™ and placebo after 12 weeks of supplementation. The secondary objectives were the difference in serum LDL-C, blood pressure, triglycerides, HDL-C, total cholesterol and in endothelial vasodilation as measured by the EndoPAT from baseline to week eight and week 12 between Farlong NotoGinseng™ and placebo.
to receive the latest news & offers
© 2020 Farlong Pharmaceutical. All rights reserved. Terms & Conditions
